Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: Can PSA and PSA density help in patient selection?

Nuclear Medicine Communications

Volumn 34, Issue 8, 2013, Pages 733-740

  Calabria, Ferdinando ^a   Chiaravalloti, Agostino ^b   Tavolozza, Mario ^b   Ragano Caracciolo, Cristiana ^b   Schillaci, Orazio ^a,b  

^a IRCCS NEUROMED   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

F 18 choline; Positron emission tomography computed tomography; Prostate cancer; Prostate specific antigen; Prostate specific antigen density; Staging

Indexed keywords

CHOLINE F 18; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASES; DISTANT METASTASIS; EXTRAPROSTATIC DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; PATIENT SELECTION; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM STAGING; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84879977554     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283620d5e     Document Type: Article

References (28)

1. Jemal A, Murray T,Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55:10-30.
2. Beauregard JM, Williams SG, Degrado TR, Roselt P, Hicks RJ. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol 2010; 54:325-332.
3. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, et al. [18F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33:1387-1398.
4. Balogova S, Huchet V, Kerrou K, Nataf V, Gutman F, Antoine M, et al. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun 2010; 31:389-397.
5. Kolthammer JA, Corn DJ, Tenley N,Wu C, Tian H,Wang Y, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging 2011; 38:1248-1256.
6. Schillaci O, Calabria F, Tavolozza M, Ciccio C, Carlani M, Caracciolo CR, et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010; 31:39-45.
7. Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008; 113:895-904.
8. Husarik DB, Miralbell R, Dubs M, John H, Giger OT, Gelet A, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:253-263.
9. Scattoni V, Picchio M, Suardi N, Messa C, Freschi M, Roscigno M, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007; 52:423-429.
10. Tuncel M, Souvatzoglou M, Herrmann K, Stollfuss J, Schuster T,Weirich G, et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008; 35:689-695.
11. Calabria F, D'Auria S, Sannino P, Schillaci O. A case of thymoma detected by 18F-choline positron emission tomography/computed tomography. Eur J Nucl Med Mol Imaging 2011; 38:602.
12. Schillaci O, Calabria F, Tavolozza M, Caracciolo CR, Finazzi Agro E, Miano R, et al. Influence of PSA, PSA velocity and PSA doubling time on contrastenhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39: 589-596.
13. Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009; 50:1394-1400.
14. Mertens K, Slaets D, Lambert B, Acou M, De Vos F, I Goethals. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging 2010; 37:2188-2193.
15. Chang JS, Choi H, Chang YS, Kim JB, Oh MM, Moon DG, et al. Prostatespecific antigen density as a powerful predictor of extracapsular extension and positive surgical margin in radical prostatectomy patients with prostatespecific antigen levels of less than 10 ng/ml. Korean J Urol 2011; 52: 809-814.
16. Giannarini G, Scott CA, Moro U, Pertoldi B, Beltrami CA, Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer? Urol Oncol 2008; 26:353-360.
17. Igerc I, Kohlfurst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, et al. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35:976-983.
18. Martorana G, Schiavina R, Corti B, Farsad M, Salizzoni E, Brunocilla E, et al. 11C-Choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176:954-960.
19. Beheshti M, Imamovic L, Broinger G, Vali R,Waldenberger P, Stoiber F, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254:925-933.
20. Steuber T, Schlomm T, Heinzer H, Zacharias M, Ahyai S, Chun KF, et al. [F18]-Fluoroethylcholine combined in-line PET-CT scan for detection of lymph-node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology based study. Eur J Cancer 2010; 46:449-455.
21. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, Briganti A, et al. 11C-Choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54:392-401.
22. De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003; 44:331-335.
23. Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, et al. [18F]-Fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010; 106:639-643.
24. Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, et al. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46:1642-1649.
25. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. BJU Int 2012; 110:1262-1269.
26. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol 2010; 12:98-107.
27. Goya M, Ishii G, Miyamoto S, Hasebe T, Nagai K, Yonou H, et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 2006; 66:1573-1584.
28. Kotb AF, Tanguay S, Luz MA, KassoufW, Aprikian AG. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance. Prostate Cancer Prostatic Dis 2011; 14:53-57.